To evaluate the accuracy of magnetic resonance imaging in determining the size and shape of localized prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Subjects were 114 men who all had multi-parametric MRI before radical prostatectomy, with patient-specific mold processing of the specimen, 2013-2015. T2-weighted images were used to contour the prostate capsule and cancer-suspicious regions of interest (ROIs). The contours were used to design and 3D-print custom molds, which permitted alignment of excised prostates with MR images. Tumors were reconstructed in 3D from digitized whole-mount sections. Tumors were then matched with ROIs and their relative geometries were compared.
222 tumors were evident on whole-mount sections, 118 of which had been identified on MRI. For the 118 ROIs, the mean volume was 0.8 cc and the longest 3D diameter was 17 mm. However, for matched pathologic tumors, most of which were GS ≥ 3+4, the mean volume was 2.5 cc and the longest 3D diameter was 28 mm. The median tumor had a 13.5 mm maximal extent beyond the MRI contour, and 80% of cancer volume from matched tumors was outside of ROI boundaries. Size estimation was most accurate in the axial plane, and least accurate along the base-apex axis.
MRI consistently underestimates the size and extent of prostate tumors. Prostate cancer foci had an average diameter 11 mm longer and a volume 3 times greater than T2-weighted MRI segmentations. These results may have important implications for the assessment and treatment of prostate cancer.
The Journal of urology. 2016 Jul 30 [Epub ahead of print]
Alan Priester, Shyam Natarajan, Pooria Khoshnoodi, Daniel J Margolis, Steven S Raman, Robert E Reiter, Jiaoti Huang, Warren Grundfest, Leonard S Marks
University of California Los Angeles, Department of Bioengineering., University of California Los Angeles, Department of Bioengineering; David Geffen School of Medicine, Department of Urology., David Geffen School of Medicine, Department of Radiological Sciences., David Geffen School of Medicine, Department of Radiological Sciences., David Geffen School of Medicine, Department of Radiological Sciences., David Geffen School of Medicine, Department of Urology., Duke University School of Medicine, Department of Pathology., University of California Los Angeles, Department of Bioengineering., David Geffen School of Medicine, Department of Urology.